OrthoLogic
This article was originally published in The Gray Sheet
Executive Summary
FDA requests additional information regarding firm's premarket approval application for the OrthoLogic 1000B device, to be used in treating non-union fractures. No deficiencies were noted at FDA's November 1992 good manufacturing practices inspection for the PMA, which was filed in November 1991. The Phoenix, Arizona firm also is conducting clinicals of the device for delayed-union fractures (patients who are between five and nine months post-injury) and open comminuted tibial fractures. In addition, OrthoLogic has recently initiated trials of SpinaLogic 1000 for adjunctive use in spinal fusion therapy.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.